Posted on 9/29/20
Ironwood Is Worth A Look As A Speculative Investment
SummaryA catalyst is expected for Ironwood, in that it expects an IDMC decision for its phase 3 study IW-3718-302 using IW-3718 to treat patients with refractory . . .
Posted on 8/26/20
Novavax Continues Progress: Latest COVID-19 Data Shows Encouraging Signs Of Advancement
SummaryNovavax achieved positive preliminary data in patients with COVID-19.Early data shows that all those who were given NVX-CoV2373 achieved anti-spike IgG antibodies and neutralization titers.Novavax expanded . . .
Posted on 8/26/20
Novavax Continues Progress: Latest COVID-19 Data Shows Encouraging Signs Of Advancement
SummaryNovavax achieved positive preliminary data in patients with COVID-19.Early data shows that all those who were given NVX-CoV2373 achieved anti-spike IgG antibodies and neutralization titers.Novavax expanded . . .
Posted on 5/14/20
Novavax Secures COVID-19 Funding And Provides Additional Value With Eventual BLA Filing Of NanoFlu Vaccine
SummaryNovavax received $384 million in funding from the Coalition of Epidemic Preparedness Innovations to develop NVX-CoV2373 as a vaccine for COVID-19.Matrix-M is a proprietary technology of . . .
Posted on 2/27/20
Bristol-Myers' Liso-Cel Given Priority Review, Ability To Change Scope Of Treatment
SummaryThe FDA accepted the BLA for liso-cel to treat patients with relapsed/refractory diffuse large B-cell lymphoma.A PDUFA date for liso-cel for the treatment of patients with . . .
Posted on 12/17/19
bluebird bio's Advancement With Zynteglo Gene Therapy Is Properly Set Up For Commercial Success
Summarybluebird bio announced a positive, long-term follow-up of 5 years for beta-thalassemia patients who have been transfusion-free for an extended period of time.The rolling BLA submission . . .
Posted on 12/17/19
Merck's Latest $2.7-Billion Buy Of ArQule Brings About Precision Targeted And Diversified Approach To Cancer Therapy
Summary Merck announced that it would spend $2.7 billion to acquire ArQule, which is a precision-focused biotech targeting indications with high unmet medical need. The acquisition . . .
Posted on 12/17/19
Merck's Latest $2.7-Billion Buy Of ArQule Brings About Precision Targeted And Diversified Approach To Cancer Therapy
SummaryMerck announced that it would spend $2.7 billion to acquire ArQule, which is a precision-focused biotech targeting indications with high unmet medical need.The acquisition brings about . . .
Posted on 11/27/19
Novartis' Latest Acquisition Of The Medicines Company Sets It Up For A Large Market
Summary Novartis announced that it would acquire The Medicines Company for $9.7 billion or for $85 per share, which was a 25% premium from Friday's close. . . .
Posted on 11/27/19
Novartis' Latest Acquisition Of The Medicines Company Sets It Up For A Large Market
Summary Novartis announced that it would acquire The Medicines Company for $9.7 billion or for $85 per share, which was a 25% premium from Friday's close. . . .
Posted on 11/27/19
Novartis' Latest Acquisition Of The Medicines Company Sets It Up For A Large Market
SummaryNovartis announced that it would acquire The Medicines Company for $9.7 billion or for $85 per share, which was a 25% premium from Friday's close.The acquisition . . .
Posted on 11/4/19
Johnson & Johnson's Xarelto Gains Another FDA Approved Indication, Needs Additional Nods Under Its Belt
Summary Johnson & Johnson received FDA approval for its drug Xarelto to treat blood clot patients with acute illness who are either hospitalized or discharged from . . .
Posted on 11/4/19
Johnson & Johnson's Xarelto Gains Another FDA Approved Indication, Needs Additional Nods Under Its Belt
SummaryJohnson & Johnson received FDA approval for its drug Xarelto to treat blood clot patients with acute illness who are either hospitalized or discharged from the . . .
Posted on 10/31/19
Johnson & Johnson's Xarelto Gains Another FDA Approved Indication
Johnson & Johnson (JNJ) and its partner Bayer AG (OTCPK:BAYRY) announced that it received FDA approval for another indication for one of its blood clot drugs . . .
Posted on 10/31/19
Johnson & Johnson's Xarelto Gains Another FDA Approved Indication
Johnson & Johnson (JNJ) and its partner Bayer AG (OTCPK:BAYRY) announced that it received FDA approval for another indication for one of its blood clot drugs . . .
Posted on 10/29/19
Pfizer's Latest Data For JAK Inhibitor Drug Lines It Up To Take On Rivals
Summary Pfizer achieved positive results from its phase 3 JADE MONO-1 study using Abrocitinib to treat patients with moderate to severe atopic dermatitis. The primary endpoint . . .
Posted on 10/29/19
Pfizer's Latest Data For JAK Inhibitor Drug Lines It Up To Take On Rivals
SummaryPfizer achieved positive results from its phase 3 JADE MONO-1 study using Abrocitinib to treat patients with moderate to severe atopic dermatitis.The primary endpoint of the . . .
Posted on 10/9/19
Johnson & Johnson's Nod For Prostate Cancer Drug May Offer Hope To Specific Patients
Summary Johnson & Johnson obtained FDA approval for Erleada plus androgen deprivation therapy to treat patients with metastatic castration-sensitive prostate cancer. FDA approval of Erleada was . . .
Posted on 10/9/19
Johnson & Johnson's Nod For Prostate Cancer Drug May Offer Hope To Specific Patients
SummaryJohnson & Johnson obtained FDA approval for Erleada plus androgen deprivation therapy to treat patients with metastatic castration-sensitive prostate cancer.FDA approval of Erleada was based on . . .
Posted on 9/16/19
Pfizer Looks To Expand Market Opportunity For Its Blockbuster Drug Xtandi
Summary The FDA has accepted review of the sNDA for Xtandi to treat patients with metastatic hormone-sensitive prostate cancer. Xtandi was given Priority Review by the . . .
Posted on 9/16/19
Pfizer Looks To Expand Market Opportunity For Its Blockbuster Drug Xtandi
SummaryThe FDA has accepted review of the sNDA for Xtandi to treat patients with metastatic hormone-sensitive prostate cancer.Xtandi was given Priority Review by the FDA for . . .
Posted on 8/14/19
Athenex: Latest Data Makes A Paradigm Shift In Current Standard Of Care For Cancer Treatment
SummaryAthenex reported positive results in a phase 3 study using oral paclitaxel to treat patients with metastatic breast cancer.The key advantage of the company involves its . . .
Posted on 6/27/19
Merck Throws Its Hat Into The Ring With Keytruda For Treating Subset Of Lung Cancer Patients
Summary Merck Announced FDA approval for Keytruda as a third-line therapy for patients with SCLC. SCLC accounts for about 10% to 15% of the entire lung . . .
Posted on 6/27/19
Merck Throws Its Hat Into The Ring With Keytruda For Treating Subset Of Lung Cancer Patients
SummaryMerck Announced FDA approval for Keytruda as a third-line therapy for patients with SCLC.SCLC accounts for about 10% to 15% of the entire lung cancer market.A . . .
Posted on 6/27/19
Johnson & Johnson Looks To Blood Cancer Drug Successor With Early-Stage Deal
Summary Johnson & Johnson teams up again with Genmab, this time to bring a potential successor to Darzalex known as HexaBody-CD38. The reasoning for developing HexaBody-CD38 . . .
Posted on 6/27/19
Johnson & Johnson Looks To Blood Cancer Drug Successor With Early-Stage Deal
SummaryJohnson & Johnson teams up again with Genmab, this time to bring a potential successor to Darzalex known as HexaBody-CD38.The reasoning for developing HexaBody-CD38 is to . . .
Posted on 6/18/19
Pfizer's Acquisition Of Array BioPharma: An Inevitable Deal
Summary Pfizer acquires Array BioPharma for $48 per share, which brings the value of the deal to $11.4 billion. The acquisition of Array gives solid drugs . . .
Posted on 6/18/19
Pfizer's Acquisition Of Array BioPharma: An Inevitable Deal
SummaryPfizer acquires Array BioPharma for $48 per share, which brings the value of the deal to $11.4 billion.The acquisition of Array gives solid drugs with a . . .
Posted on 6/13/19
Celgene's Long Journey Through Regulatory Filings For Ozanimod Might Finally Pay Off
Summary Celgene finally gets the FDA on board with its regulatory application for potential approval of ozanimod to treat relapsing forms of multiple sclerosis; PDUFA date . . .
Posted on 6/13/19
Celgene's Long Journey Through Regulatory Filings For Ozanimod Might Finally Pay Off
SummaryCelgene finally gets the FDA on board with its regulatory application for potential approval of ozanimod to treat relapsing forms of multiple sclerosis; PDUFA date set . . .
Posted on 6/13/19
Merck Makes Bold Acquisition, Which If It Succeeds Could End Up Paying Off
Summary Merck agreed to acquire Tilos Therapeutics for $773 million, which opens up the possibility of using anti-LAP antibodies to target cancer, fibrosis, and autoimmune diseases. . . .
Posted on 6/13/19
Merck Makes Bold Acquisition, Which If It Succeeds Could End Up Paying Off
SummaryMerck agreed to acquire Tilos Therapeutics for $773 million, which opens up the possibility of using anti-LAP antibodies to target cancer, fibrosis, and autoimmune diseases.The ability . . .
Posted on 6/12/19
bluebird bio Breezes By For European Approval Of Its Gene Therapy Zynteglo
Summary bluebird bio gains regulatory approval in Europe for its gene therapy Zynteglo to treat patients with beta-thalassemia, which was the very first approval for it. . . .
Posted on 6/12/19
bluebird bio Breezes By For European Approval Of Its Gene Therapy Zynteglo
Summarybluebird bio gains regulatory approval in Europe for its gene therapy Zynteglo to treat patients with beta-thalassemia, which was the very first approval for it.A majority . . .
Posted on 6/12/19
Merck And Private Partner NGM Hope For Once-Monthly Dosing NASH Drug
Summary Merck has been able to license a drug from NGM Bio, now known as MRK-3655, which can be used to treat patients with both Type . . .
Posted on 6/12/19
Merck And Private Partner NGM Hope For Once-Monthly Dosing NASH Drug
SummaryMerck has been able to license a drug from NGM Bio, now known as MRK-3655, which can be used to treat patients with both Type 2 . . .
Posted on 5/23/19
Pfizer Posts Positive Phase 3 Study In Eczema, Catalysts Remain In Second Half Of 2019
Summary Pfizer announced that it had achieved positive top-line results from its phase 3 study using abrocitinb to treat patients with atopic dermatitis (eczema). Top-line results . . .
Posted on 5/23/19
Pfizer Posts Positive Phase 3 Study In Eczema, Catalysts Remain In Second Half Of 2019
SummaryPfizer announced that it had achieved positive top-line results from its phase 3 study using abrocitinb to treat patients with atopic dermatitis (eczema).Top-line results showed that . . .
Posted on 5/21/19
Pfizer Nabs Regulatory Approval For Tafamidis, An FDA First Is Achieved
Summary Pfizer obtained FDA approval for drugs Vyndaqel and Vyndamax to treat patients with transthyretin amyloid cardiomyopathy. Vyndaqel and Vyndamax are the first drugs approved to . . .
Posted on 5/21/19
Pfizer Nabs Regulatory Approval For Tafamidis, An FDA First Is Achieved
SummaryPfizer obtained FDA approval for drugs Vyndaqel and Vyndamax to treat patients with transthyretin amyloid cardiomyopathy.Vyndaqel and Vyndamax are the first drugs approved to treat ATTR-CM . . .
Posted on 5/16/19
Pfizer Acquires Therachon, Looks To Add To Rare Disease Pipeline
Pfizer (PFE) acquired a private biotech by the name of Therachon. The reason for doing so is to add several rare disease drugs into its pipeline.
Posted on 5/16/19
Pfizer Acquires Therachon, Looks To Add To Rare Disease Pipeline
Pfizer (PFE) acquired a private biotech by the name of Therachon. The reason for doing so is to add several rare disease drugs into its pipeline.
Posted on 4/30/19
Johnson & Johnson Comes Out Of Gate With First Approval For Targeted Bladder Cancer Therapy
Johnson & Johnson (JNJ) has made substantial groundbreaking news, because it was the first to receive FDA approval for metastatic bladder cancer that deals with specific . . .
Posted on 4/30/19
Johnson & Johnson Comes Out Of Gate With First Approval For Targeted Bladder Cancer Therapy
Johnson & Johnson (JNJ) has made substantial groundbreaking news, because it was the first to receive FDA approval for metastatic bladder cancer that deals with specific . . .
Posted on 4/18/19
Johnson & Johnson Looks To Help Type 2 Diabetes Patients With Key Advancement
Johnson & Johnson announced that it had achieved positive results in a phase 3 study using INVOKANA along with standard of care to treat type 2 . . .
Posted on 4/18/19
Johnson & Johnson Looks To Help Type 2 Diabetes Patients With Key Advancement
Johnson & Johnson announced that it had achieved positive results in a phase 3 study using INVOKANA along with standard of care to treat type 2 . . .
Posted on 4/12/19
bluebird bio's CHMP Response Lays Groundwork For Its First Gene Therapy Approval
Summary bluebird bio's Zynteglo receives positive CHMP opinion for approval of Zynteglo to treat transfusion dependent beta-thalassemia patients. The European Commission is expected to make its . . .
Posted on 4/12/19
bluebird bio's CHMP Response Lays Groundwork For Its First Gene Therapy Approval
Summarybluebird bio's Zynteglo receives positive CHMP opinion for approval of Zynteglo to treat transfusion dependent beta-thalassemia patients.The European Commission is expected to make its final decision . . .
Posted on 4/12/19
Celgene And Acceleron: BLA Luspatercept Has Strong Potential
Summary Celgene announced that it had submitted its BLA to receive FDA approval for luspatercept to treat patients with two diseases that are associated with anemia. . . .
Posted on 4/12/19
Celgene And Acceleron: BLA Luspatercept Has Strong Potential
SummaryCelgene announced that it had submitted its BLA to receive FDA approval for luspatercept to treat patients with two diseases that are associated with anemia.If luspatercept . . .
Washington DC
